Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Follow-On Biologics White Paper From FDA Could Be Delayed Until Fall

This article was originally published in The Pink Sheet Daily

Executive Summary

Policy implementation is likely to require agency action before legislative initiatives, according to Reed Smith attorney Deborah Shelton.

You may also be interested in...



FDA Drops Plans For Follow-On Biologics Policy

The agency does not plan to release documents or announce policies concerning follow-on proteins "in the near future," Deputy Commissioner Gottlieb says.

FDA Drops Plans For Follow-On Biologics Policy

The agency does not plan to release documents or announce policies concerning follow-on proteins "in the near future," Deputy Commissioner Gottlieb says.

Crawford Resigns; NCI Director Von Eschenbach Named To Top FDA Spot

Von Eschenbach appointed to be acting FDA commissioner following the Sept. 23 resignation of Lester Crawford.

Related Content

Topics

UsernamePublicRestriction

Register

GB140150

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel